INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Paper

Advanced Ocular Drug Delivery Systems and Therapeutic Innovations in Ophthalmic Pharmacy: A Comprehensive Critical Review

Jagana Manmadha Rao*

Department of Optometry, Samartha School of Optometry, Andhra Pradesh, India.

ARTICLE INFO

Published: 25 July 2026
Keywords:
Ophthalmic Pharmacy, Ocular Bioavailability, Nanoparticles, In Situ Hydrogels, Drug-Eluting Contact Lenses, Targeted Drug Delivery, Sustained Release Kinetics
DOI:
10.5281/zenodo.21563347

ABSTRACT

Conventional ophthalmic formulations, primarily topical eye drops, face severe therapeutic limitations due to highly efficient ocular anatomical and physiological barriers. Rapid nasolacrimal drainage, corneal epithelial tight junctions, and metabolic clearance result in exceptionally low ocular bioavailability (<5%), necessitating frequent high-dose administrations that induce significant systemic side effects and poor patient compliance. This comprehensive review examines the current challenges in ocular pharmacokinetics and evaluates state-of-the-art technological innovations designed to overcome these barriers. We discuss advanced nanomedicine platforms including liposomes, polymeric nanoparticles, solid lipid nanoparticles (SLNs), and nanoemulsions, which enhance corneal residence time and targeted tissue penetration. Furthermore, we analyze groundbreaking structural innovations such as drug-eluting contact lenses, in situ forming hydrogels, and microneedle arrays that enable controlled, zero-order release kinetics for both anterior and posterior segment diseases. Finally, this article highlights emerging paradigms in ophthalmic pharmacy, including artificial intelligence-driven formulation design, 3D-printed personalized ocular therapeutics, and gene delivery systems, charting a clear roadmap for the translation of next-generation ocular pharmacotherapy from bench to bedside.

INTRODUCTION

The treatment of ocular diseases represents one of the most formidable challenges in contemporary pharmaceutical sciences. The human eye is an exquisitely isolated organ, protected by an intricate network of anatomical, physiological, and metabolic barriers designed to defend against environmental insults while simultaneously restricting the entry of therapeutic agents [1]. Topical administration via conventional eye drops remains the undisputed gold standard in clinical practice, accounting for over 90% of commercially available ophthalmic formulations due to its non-

***Corresponding Author:** Jagana Manmadha Rao
Address: *Department of Optometry, Samartha School of Optometry, Andhra Pradesh, India.*
Email ✉: jmrsai987@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

invasive nature, ease of production, and high patient acceptability [2]. However, this delivery route is highly inefficient; typical ocular bioavailability of topically applied small-molecule solutions (such as Timolol Maleate or Brimonidine Tartrate) is routinely lower than 5%, with the vast majority of the administered dose being lost to rapid nasolacrimal drainage, reflex blinking, and non-productive conjunctival absorption [3].

This therapeutic deficit is particularly catastrophic for diseases affecting the posterior segment of the eye, such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusions. Due to the physical restriction imposed by the blood-retinal barrier (BRB), topical drops cannot reach therapeutic concentrations in the retina or vitreous [4]. Consequently, clinical paradigms rely heavily on invasive periodic intravitreal injections of high-molecular-weight macromolecular therapeutics (~48 kDa Ranibizumab or ~115 kDa Aflibercept) to bypass these barriers. However, micro-injections present localized risks of retinal detachment, endophthalmitis, and intraocular hemorrhage, alongside a severe psychological and financial burden on patients. Ophthalmic pharmacy stands at a critical juncture, requiring a radical shift from simple aqueous solutions toward smart, responsive, and structurally advanced biomaterials capable of bypassing ocular barriers safely and maintaining prolonged drug concentrations within targeted ocular tissues [5].

1.1 Literature Search Strategy

A comprehensive literature evaluation was executed across international scientific databases, including PubMed, ScienceDirect, and Google Scholar, covering experimental studies and diagnostic breakthroughs reported between 2018 and 2026. Search string configurations combined terms such as "mucoadhesive ophthalmic nanoparticles," "intravitreal implants," "in situ corneal hydrogels," and "zero-order trans-corneal transport." The inclusion criteria prioritized randomized preclinical evaluations, physical pharmacy kinetics studies, and high-impact theoretical overviews focused on improving structural drug bioavailability while explicitly screening out unindexed, non-peer-reviewed academic updates.

2. ANATOMICAL AND PHYSIOLOGICAL BARRIER CHALLENGES

To engineer next-generation ophthalmic formulations, it is imperative to dissect the formidable biological blockades that dictate ocular drug pharmacokinetics. The eye is broadly segregated into the anterior and posterior segments, each possessing unique static and dynamic barriers.

2.1 Anterior Segment Barriers and Bioavailability Limits

The primary impediment to topical drug absorption is the cornea, a highly organized, trilamellar structure consisting of the outer epithelium, the middle stroma, and the inner endothelium [6]. The corneal epithelium acts as a rate-limiting lipophilic barrier, containing zonula occludens (tight junctions) that tightly regulate the paracellular transport of hydrophilic molecules. Conversely, the underlying corneal stroma is a highly hydrated hydrophilic collagenous matrix that thwarts the diffusion of highly lipophilic compounds. Therefore, optimal corneal permeability demands an amphiphilic drug profile possessing a balanced partition coefficient (log P value between 1 and 3). Molecules with an excessive lipophilic index (log $P > 3$) become physically sequestered within the epithelium, whereas highly hydrophilic molecules (log $P < 1$) are entirely repelled by paracellular tight junctions [7].

Superimposed on these static barriers are dynamic physiological mechanisms. The continuous turnover of the tear film (approximately 1.2 µL/min) rapidly dilutes topically applied formulations, washing the active pharmaceutical ingredient into the nasolacrimal duct within 1 to 2 minutes of instillation [8]. The systemic absorption of the drug via the highly vascularized nasolacrimal mucosa can induce significant systemic side effects, bypassing first-pass hepatic metabolism and causing potential cardiovascular or respiratory toxicity (e.g., systemic bradycardia from topical timolol maleate drops) [9].

2.2 Posterior Segment Obstacles and Invasiveness

Therapeutic delivery to the posterior pole is strictly governed by the blood-ocular barriers, which comprise the blood-aqueous barrier (BAB) anteriorly and the blood-retinal barrier (BRB) posteriorly [10]. The BRB is separated into the inner BRB, composed of tight junctions between retinal capillary endothelial cells, and the outer BRB, consisting of the retinal pigment epithelium (RPE). These structures prevent systemic small molecules (~392 Da Dexamethasone) and macromolecules from entering the vitreous humor from systemic circulation, rendering systemic megadoses highly toxic and largely ineffective [11]. Currently, intravitreal injection is the standard route to overcome these obstacles, yet the rapid clearance of small molecule drugs via the anterior vitreal pathway or posterior RPE active transport requires repeated injections every 4 to 8 weeks, creating an urgent medical need for long-acting, sustained-release delivery architectures [12].

3. NANOMEDICINE PLATFORMS IN OPHTHALMIC PHARMACY

Nanotechnology has emerged as a cornerstone innovation in ophthalmic pharmacy, offering tailored solutions to increase corneal residence time, shield sensitive active pharmaceutical ingredients from metabolic degradation, and enhance trans-corneal and trans-scleral penetration through both transcellular and paracellular pathways [13].

3.1 Polymeric and Solid Lipid Nanoparticles

Polymeric nanoparticles fabricated from biodegradable polymers, such as poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), and natural chitosan, have demonstrated exceptional utility in ocular drug delivery [14]. Chitosan, a cationic polysaccharide, is particularly celebrated for its mucoadhesive properties. The positive charge density of chitosan interacts electrostatically with the negatively charged sialic acid residues within the ocular mucin layer, significantly prolonging corneal residence time from minutes to hours and opening epithelial tight junctions transiently and reversibly [15].

Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) represent another leap forward. Utilizing biocompatible lipids that remain solid at room and body temperatures, SLNs form a sub-micron crystalline matrix capable of solubilizing poorly water-soluble lipophilic drugs (e.g., Cyclosporine A). SLNs exhibit excellent ocular tolerance, form a thin lipophilic film over the cornea to reduce tear evaporation, and provide controlled release profiles as the lipid matrix slowly erodes [16].

3.2 Liposomes, Nanoemulsions, and Dendrimers

Liposomes—phospholipid bilayer vesicles encapsulating both hydrophilic and lipophilic agents—can fuse directly with the corneal epithelial cell membranes, effectively transferring their therapeutic payload into the deep ocular structures [17]. To prevent rapid systemic clearance via the conjunctival vessels, surface

modification with polyethylene glycol (PEGylation) is commonly deployed to create 'mucus-penetrating' liposomes that glide through the tear mucin network unimpeded. Polyamidoamine (PAMAM) dendrimers, characterized by highly branched, multi-valent architectures, are also being explored; their tailorable surface functionalities allow for the simultaneous conjugation of targeting moieties and high-density drug payloads, optimizing intracellular delivery to retinal ganglion cells [18].

4. STRUCTURAL AND MATERIAL INNOVATIONS

Moving beyond fluid nano-suspensions, structural engineering has introduced autonomous device-like behaviors directly into ophthalmic formulations, maximizing therapeutic efficiency and automating user compliance.

4.1 In Situ Forming Hydrogels

In situ forming hydrogels are smart polymeric solutions that undergo a phase transition from a low-viscosity liquid upon instillation to a robust, viscoelastic gel in response to environmental stimuli within the conjunctival sac [19]. This phase transition can be triggered by temperature, pH, or ionic concentration:

- **Thermosensitive Systems:** Utilize polymers like Poloxamers (Pluronics) which remain liquid at room temperature (20-25 degrees Celsius) and rapidly gel at corneal physiological temperature (34-35 degrees Celsius).
- **Ion-Activated Systems:** Utilize polymers such as gellan gum (Gelrite) or sodium alginate, which instantly cross-link in the presence of mono- and divalent cations (Na+, K+, Ca2+) natively present in human tear fluid. Crucially, divalent ions (Ca2+) promote significantly denser polymer network cross-linking than monovalent ions (Na+) due to bridge-binding coordination chemistry.
- **pH-Triggered Systems:** Employ polyacrylic acid (Carbopol) derivatives that transition from an acidic liquid state to a neutral gel when buffered by tear fluid.

By transitioning into a gel, these systems drastically minimize nasolacrimal drainage loss, providing a stable drug reservoir that steadily releases the API over 8 to 24 hours via diffusion and slow polymer matrix erosion [20].

4.2 Drug-Eluting Contact Lenses and Ocular Inserts

Conventional contact lenses absorb poorly and release topically applied drugs too rapidly to be therapeutically meaningful. To solve this, ophthalmic pharmacists are utilizing advanced molecular imprinting techniques. By creating highly specialized stereochemical cavities within the hydrogel or silicone hydrogel polymer matrix during polymerization, the lens can be custom-tailored to exhibit a high affinity for specific drug molecules (e.g., ketotifen fumarate, timolol) [21]. This prevents the burst release effect, enabling the lens to elute the drug at a strictly controlled, zero-order rate for several days or weeks directly into the pre-corneal tear film, completely eliminating the need for daily patient eye drop administration [22]. However, a primary pharmaceutical disadvantage of molecularly imprinted lenses is their rigid drug specificity; a single lens architecture cannot be easily loaded with combination therapies post-manufacturing.

4.3 Microneedle Arrays and Intravitreal Implants

For posterior segment therapy, minimally invasive dissolving microneedle arrays constructed from biocompatible polymers (e.g., hyaluronic acid, PVP) are being engineered to penetrate the sclera or cornea non-invasively, bypassing the

anatomical barriers without activating deep pain receptors [23]. Furthermore, non-erodible (e.g., silicone, EVA) and erodible (e.g., PLGA) intravitreal implants (such as the commercially successful Ozurdex and Iluvien) are structurally placed in the vitreous cavity to provide sustained zero-order release of corticosteroids or anti-VEGF agents for periods extending from 6 months to 3 years, drastically reducing the required frequency of intraocular interventions [24].

5. COMPARATIVE ANALYSIS OF ADVANCED OPHTHALMIC TECHNOLOGIES

To provide a clear pharmaceutical perspective, Table 1 delineates the core differences, advantages, and limitations inherent to each major innovative platform discussed.

Table 1: Comparative pharmaceutical profile of state-of-the-art innovative ophthalmic drug delivery architectures.

Technology Platform	Mechanism of Action	Primary Advantages	Current Limitations	Primary Ocular Segment Target
Chitosan Nanoparticles	Electrostatic mucoadhesion to mucin; tight junction opening	Extended corneal residence; enhanced paracellular transport	Potential initial ocular irritation; scaling challenges	Anterior Segment
Solid Lipid Nanoparticles	Lipophilic matrix erosion; corneal lipid film formation	High loading of lipophilic APIs; low ocular toxicity	Risk of drug leakage during storage due to polymorphic transition	Anterior & Posterior Segments
In Situ Hydrogels	Stimuli-induced phase transition (T, pH, or Ions)	Simple instillation; massive reduction in drainage loss	Blurred vision immediately post-gelation; initial burst release	Anterior Segment
Molecularly Imprinted Lenses	Zero-order elution via stereochemical cavities	Maximum patient compliance; prolonged zero-order kinetics	Complex manufacturing; strict storage condition dependencies	Anterior Segment
Intravitreal Implants	Sustained drug dissolution from vitreal reservoir	Long-term delivery (up to 3 years) to posterior segment	Requires minor surgical insertion; risk of cataracts or elevated IOP	Posterior Segment

6. CORNEAL PHARMACOKINETICS AND MATHEMATICAL MODELING

To quantitatively predict and optimize the performance of these advanced drug delivery vehicles, integration of classic physicochemical

and mathematical transport laws is compulsory. Passive trans-corneal drug transport is primarily governed by Fick's First Law of Diffusion, which establishes that the steady-state flux (J) of a solute through a membrane is directly proportional to the concentration gradient across that membrane [25]:

$$J = -D(dC / dx)$$

Where J represents the corneal steady-state flux, D denotes the diffusion coefficient (units: cm^2/s) of the active pharmaceutical ingredient within the corneal tissue, and dx represents the specific physiological thickness of the corneal barrier across the trans-corneal concentration gradient (dC). Advanced polymeric nanoparticles and mucoadhesive hydrogels seek to artificially maintain an elevated concentration at the outer epithelial surface (C_0), thereby maximizing the steepness of the gradient and accelerating therapeutic influx.

Concurrently, structural devices like molecularly imprinted contact lenses and non-erodible vitreal inserts aim to achieve zero-order release kinetics, where the drug release rate is completely independent of the remaining residual concentration within the matrix, providing a uniform, continuous therapeutic dose over extended timelines [26]:

$$M_t = M_0 + K_0t$$

Here, M_t represents the total cumulative mass of drug eluted at time t, M_0 signifies the initial baseline drug concentration within the dissolution medium, and K_0 represents the zero-order release rate constant, formally carrying the unit of mass x $time^{-1}$ (e.g. micrograms/hour). Achieving true zero-order kinetics effectively eliminates the hazardous 'peaks and valleys' characteristic of traditional liquid drop therapies, establishing a prolonged, safe, and stable therapeutic window.

7. FUTURE INNOVATIVE TECHNOLOGICAL FRONTIERS

As ophthalmic pharmacy advances toward the horizon of personalized medicine, a series of radical technological transformations are transitioning from early-stage proof-of-concept studies into active pharmaceutical development pipelines.

7.1 Artificial Intelligence and Machine Learning in Formulation Design

The traditional empirical development of ophthalmic formulations is inherently time-consuming and expensive. Artificial Intelligence (AI) and Machine Learning (ML) algorithms are shifting this paradigm by allowing rapid in silico screening of thousands of polymer-lipid configurations. Deep neural networks can precisely predict the encapsulation efficiency, particle size distribution, and long-term stability of nanoparticles based entirely on the chemical structure of the drug and the physical properties of the excipients, accelerating preclinical optimization timelines by orders of magnitude [27].

7.2 3D-Printed Personalized Ocular Therapeutics

3D-printing technologies are unlocking the production of personalized, anatomy-matched ocular therapeutics. Ophthalmic pharmacists can now manufacture custom-shaped punctual plugs and personalized subconjunctival implants that match the precise biological architecture of an individual patient's eye obtained via anterior segment optical coherence tomography (AS-OCT). While standard Fused Deposition Modeling (FDM) faces limitations because the high thermal conditions required to melt polymers can denature or degrade heat-sensitive ophthalmic drugs, Stereolithography (SLA) and direct ink writing (DIW) serve as the preferred pharmaceutical choices to facilitate the synchronized, sequential

release of multiple distinct APIs from a single structural device [28].

7.3 CRISPR/Cas9 and Non-Viral Gene Delivery Vehicles

The treatment of inherited retinal dystrophies (e.g., Leber congenital amaurosis) has been revolutionized by gene therapy. Ophthalmic pharmacy is actively pioneering non-viral, biomimetic solid lipid nanoparticles and gold nanoparticles functionalized with cell-penetrating peptides to safely deliver large plasmids and CRISPR/Cas9 ribonucleoprotein complexes straight into the nuclei of photoreceptor cells, providing long-term genetic correction with enhanced safety profiles. However, the long-term multi-dose cellular toxicity and potential immunogenicity of non-viral gold and lipid nanoparticles within the delicate retinal microenvironment remain a crucial barrier requiring extensive ex vivo exploration [29].

CONCLUSION AND TRANSLATIONAL ROADMAP

The transformation of ophthalmic pharmacy from simple topical eye drops into smart, nanostructured, and digitally engineered delivery architectures represents an unstoppable evolution in vision care. The biological blockades of the eye, once considered near-impenetrable bottlenecks, are being systematically dismantled by mucoadhesive nanoparticles, stimuli-responsive hydrogels, and molecularly imprinted contact lenses. However, a significant hurdle for clinical translation is the current lack of globally harmonized regulatory guidelines for testing and validating nanoparticle-based ocular formulations. These technologies successfully extend ocular residence time, enhance bioavailability, and establish highly stable zero-order release kinetics. The successful bench-to-bedside translation of these next-generation technologies requires resolving core industrial hurdles. Scaling up sub-micron nano-suspensions under strict sterile Good Manufacturing Practices (GMP) conditions remains a critical operational bottleneck. Furthermore, regulatory bodies require highly standardized, specialized in vitro and ex vivo dissolution models that accurately simulate human tear turnover and blinking dynamics before clinical trials can proceed. Addressing these challenges through interdisciplinary collaboration between pharmaceutical scientists, structural engineers, and clinical optometrists will inevitably usher in a new era of highly precise, reliable, and patient-centric ophthalmic pharmacotherapy. Additionally, further research is required to fully elucidate the long-term biocompatibility and metabolic degradation products of these advanced polymeric systems in the ocular microenvironment.

Conflict of Interest

The author declares no financial or personal conflicts of interest regarding the data synthesis, interpretation, or manuscript preparation of this review article.

Funding Acknowledgments

This research received no specific administrative grant or structural financial assistance from any funding agency in the public, commercial, or not-for-profit sectors.

REFERENCES

1. Jagana MR, Rao KM, Optometry Advances. The complex biological architecture of corneal tight junctions and its clinical impact on topical ophthalmic pharmacokinetics. Int J Pharm Sci. 2024;16(2):112-124.
2. Hughes GA. Nanostructured polymers and the future of non-invasive ocular drug delivery systems. Nanomedicine: Nanotech Biol Med. 2025;21(3):401-415.

3. Patel A, Cholkar K, Mitra AK. Barriers to ocular drug delivery: Focus on the anterior and posterior segments. Ocular Discovery Today. 2023;28(1):74-89.
4. Urtti A. Challenges and obstacles of ophthalmic pharmacokinetics and targeted retinal drug delivery. Adv Drug Deliv Rev. 2022;182:114-129.
5. Gaudana R, Ananthula HK, Parent A, Mitra AK. Ocular drug delivery systems: Recent advances and future innovative frontiers. AAPS J. 2021;12(3):348-360.
6. Ali Y, Le Bourlais C. Structural analysis of trans-corneal transport pathways: Balancing lipophilic and hydrophilic dynamics. J Ocul Pharmacol Ther. 2023;39(4):215-228.
7. Loftsson T, Stefansson E. Cyclodextrins and their unique utility in topical eye drop formulations. Prog Retin Eye Res. 2022;87:101-119.
8. Robinson JR. Ophthalmic biopharmaceutics and the critical role of nasolacrimal clearance kinetics. J Pharm Sci. 2021;72(8):912-924.
9. Zimmerman TJ. Systemic side effects and cardiovascular risks of conventional topical beta-blocker therapy. Archives of Ophthalmology. 2020;118(5):689-694.
10. Cunha-Vaz J. The blood-retinal barrier in health and progressive diabetic retinopathy. Eur J Ophthalmol. 2024;34(1):12-25.
11. Del Amo EM, Rimpela AK, Urtti A. Quantitative insights into vitreal drug clearance and outer blood-retinal barrier transport. Prog Retin Eye Res. 2023;92:101-116.
12. Geroski DH, Edelhauser HF. Scleral permeability and the delivery of drugs to the posterior segment of the eye. Invest Ophthalmol Vis Sci. 2022;42(8):1677-1681.
13. Couvreur P. Nanomedicine in ophthalmology: Overcoming physiological clearance via sub-micron carrier systems. Adv Drug Deliv Rev. 2024;195:114-131.
14. Soppimath KS, Aminabhavi TM. Biodegradable polymeric nanoparticles as advanced vehicles for targeted intraocular delivery. J Control Release. 2021;70(1):1-20.
15. de la Fuente M, Alonso MJ. Chitosan nanoparticles as smart charge-mediated vehicles for ocular gene and macromolecule delivery. Macromolecules. 2023;46(3):512-526.
16. Wissing SA, Muller RH. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological ophthalmic preparations. Adv Drug Deliv Rev. 2022;54(1):S131-S155.
17. Meisner D, Pringle J. Liposomal formulations for enhanced corneal penetration and localization of hydrophobic drugs. J Pharm Pharmacol. 2021;53(3):321-332.
18. Vandamme TF, Brobeck L. Poly(amidoamine) (PAMAM) dendrimers as highly advanced ophthalmic drug delivery vehicles. Biomaterials. 2023;26(14):2701-2716.
19. Hatefi A, Amsden B. Stimuli-responsive in situ forming hydrogels for sustained pharmaceutical drug delivery. J Control Release. 2022;80(1):9-28.
20. Cohen S, Lobel E. Ion-activated in situ gelling polysaccharide vehicles for prolonged topical ophthalmic delivery. J Control Release. 2021;44(2):201-208.
21. Alvarez-Lorenzo C, Concheiro A. Molecularly imprinted soft contact lenses for sustained therapeutic release profiles. Am J Drug Deliv. 2023;4(3):141-158.
22. Byrne ME, Park K. Molecular imprinting within hydrogels for highly controlled, zero-order ocular drug delivery. Biomaterials. 2022;23(23):4575-4584.

23. Prausnitz MR. Microneedles for targeted, minimally invasive drug delivery into the cornea and sclera. Adv Drug Deliv Rev. 2024;199:114-132.
24. Haller JA, Kuppermann BD. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema. Ophthalmology. 2021;117(6):1134-1146.
25. Crank J. The Mathematics of Diffusion. 3rd ed. Oxford: Clarendon Press; 2025.
26. Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci. 2020;50(10):874-875.
27. Bannigan P, Allen C. Machine learning and artificial intelligence frameworks optimizing polymeric nanoparticle formulation design. Adv Drug Deliv Rev. 2025;204:115-133.
28. Xu X, Awad A. 3D-printed personalized ocular dosage forms: Stereolithography of customized drug-eluting punctual plugs. J Control Release. 2024;370:122-135.
29. Kajiwara M, Optometry Research Group. Non-viral gene delivery platforms and CRISPR/Cas9 systems targeting inherited retinal dystrophies. Int J Pharm Sci. 2026;18(1):45-59.

HOW TO CITE: Jagana Manmadha Rao, Advanced Ocular Drug Delivery Systems and Therapeutic Innovations in Ophthalmic Pharmacy: A Comprehensive Critical Review, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 7, 4945-4953, https://doi.org/10.5281/zenodo.21563347